We are analyzing https://link.springer.com/article/10.1007/bf03401823.

Title:
Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment | Molecular Medicine
Description:
Background Suberoylanilide hydroxamic acid (SAHA) is a prototype of the newly developed, second-generation, hybrid polar compounds. It is a novel histone deacetylase inhibitor with high potency for inducing cell differentiation of cultured murine erythroleukemia cells. Studies with SAHA have primarily been performed with hematopoietic tumor cells. Here we extent these studies with SAHA to human breast cancer cell lines in an attempt to find better therapeutic agents for breast cancer treatment. Materials and Methods Human breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-435, as well as normal cells, including the normal breast epithelial cell line MCF-10A, and fibroblasts, were treated with SAHA. Cells assayed for cell survival by using trypan blue exclusion assay, colony formation assay, and cell cycle and apoptosis analysis. The effects of SAHA on cell cycle and apoptosis regulatory proteins were examined by Western blots analysis. The identification of additional target genes was carried out by differential display (DD) and reverse transcription-polymerase chain reaction (RT-PCR). Results SAHA inhibited clonogenic growth of MCF7, MDA-MB-231, and MDA-MB-435 breast cancer cells. These cells were more sensitive to SAHA-mediated cytotoxic effects than normal breast epithelial cells and fibroblasts. The cytotoxic effects of SAHA on breast cancer cells were manifested by G1 and G2/M cell cycle arrest and eventual apoptosis. The pan-caspase inhibitor, Z-VAD.fmk, blocked SAHA-induced cell death, DNA laddering, and cleavage of poly(ADP-ribose) polymerase, indicating the involvement of caspases in SAHA-mediated apoptosis. In addition, SAHA modulated cell cycle and apoptosis regulatory proteins. For example, cyclin-dependent kinase (CDK) inhibitors p21WAF1/Cip1 and p27Kip1 were induced, and retinoblastoma protein pRb was hypophosphorylated. Moreover, SAHA induced several genes associated with differentiation and/or growth inhibition. These genes encode gelsolin, isopentenyl-diphosphate delta isomerase (IDI1), and 1,25-dihydroxyvitamin D-3 up-regulated protein 1 (VDUP1), the last two of which were identified by DD. Induction of these genes may contribute to SAHA-mediated pro-differentiating and antiproliferative effects. Conclusions SAHA induced growth inhibition, cell cycle arrest, and eventual apoptosis in human breast cancer cells, possibly by modulating cell cycle and apoptosis regulatory proteins, such as CDK inhibitors p21 and p27, pRb, and other differentiation and/or growth inhibition-associated genes, including gelsolin, IDI1 and VDUP1. This, together with the low toxicity in normal cells, suggests that SAHA might have therapeutic potential for the treatment of human breast cancers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

pubmed, google, scholar, cas, article, cell, cancer, human, cells, breast, histone, apoptosis, deacetylase, saha, res, expression, protein, gelsolin, acid, differentiation, central, biol, usa, nature, inhibitor, proteins, growth, chem, thioredoxin, cycle, genes, richon, sci, gene, asch, suberoylanilide, hydroxamic, effects, death, induced, retinoblastoma, inhibition, natl, acad, pardee, hybrid, polar, access, proc, transcriptional,

Topics {✒️}

epstein-barr virus-transformed lymphocytes month download article/chapter suberoylanilide hydroxamic acid n-methyl-n-nitrosourea dana-farber cancer institute radiation-induced g1 arrest hybrid polar compounds carcinogen-induced mammary tumorigenesis inappropriate s-phase entry g1 cyclin-dependent kinases cyclin-dependent kinase activities di-methylallyl diphosphate isomerase thioredoxin-binding protein-2/vitamin butyrate-mediated growth inhibition waf1/cip1 gene promoter isopentenyl-diphosphate delta isomerase phorbol ester-induced differentiation saha-mediated pro-differentiating cytodifferentiation agent-induced pathways atl-derived factor trans retinoic acid growth-promoting effect full article pdf tpa-induced monocytic differentiation vitamin d-regulated gene hybrid polar inducers programmed cell death janicke ru breast cancer cells autocrine growth factor cyclin-dependent kinase human breast cancers saha-mediated cytotoxic effects human isopentenyl diphosphate mammalian histone deacetylase breast cancer treatment normal human keratinocytes privacy choices/manage cookies cdk inhibitors p21 human myeloma cells anti-tumour activity hematopoietic tumor cells human bladder cancer histone deacetylase inhibitor histone deacetylase activity plzf-rar-alpha human thioredoxin homologue advanced breast cancer cell cycle arrest acute myelogenous leukemia

Questions {❓}

(1997) What’s up and down with histone deacetylation and transcription?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
         description:Suberoylanilide hydroxamic acid (SAHA) is a prototype of the newly developed, second-generation, hybrid polar compounds. It is a novel histone deacetylase inhibitor with high potency for inducing cell differentiation of cultured murine erythroleukemia cells. Studies with SAHA have primarily been performed with hematopoietic tumor cells. Here we extent these studies with SAHA to human breast cancer cell lines in an attempt to find better therapeutic agents for breast cancer treatment. Human breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-435, as well as normal cells, including the normal breast epithelial cell line MCF-10A, and fibroblasts, were treated with SAHA. Cells assayed for cell survival by using trypan blue exclusion assay, colony formation assay, and cell cycle and apoptosis analysis. The effects of SAHA on cell cycle and apoptosis regulatory proteins were examined by Western blots analysis. The identification of additional target genes was carried out by differential display (DD) and reverse transcription-polymerase chain reaction (RT-PCR). SAHA inhibited clonogenic growth of MCF7, MDA-MB-231, and MDA-MB-435 breast cancer cells. These cells were more sensitive to SAHA-mediated cytotoxic effects than normal breast epithelial cells and fibroblasts. The cytotoxic effects of SAHA on breast cancer cells were manifested by G1 and G2/M cell cycle arrest and eventual apoptosis. The pan-caspase inhibitor, Z-VAD.fmk, blocked SAHA-induced cell death, DNA laddering, and cleavage of poly(ADP-ribose) polymerase, indicating the involvement of caspases in SAHA-mediated apoptosis. In addition, SAHA modulated cell cycle and apoptosis regulatory proteins. For example, cyclin-dependent kinase (CDK) inhibitors p21WAF1/Cip1 and p27Kip1 were induced, and retinoblastoma protein pRb was hypophosphorylated. Moreover, SAHA induced several genes associated with differentiation and/or growth inhibition. These genes encode gelsolin, isopentenyl-diphosphate delta isomerase (IDI1), and 1,25-dihydroxyvitamin D-3 up-regulated protein 1 (VDUP1), the last two of which were identified by DD. Induction of these genes may contribute to SAHA-mediated pro-differentiating and antiproliferative effects. SAHA induced growth inhibition, cell cycle arrest, and eventual apoptosis in human breast cancer cells, possibly by modulating cell cycle and apoptosis regulatory proteins, such as CDK inhibitors p21 and p27, pRb, and other differentiation and/or growth inhibition-associated genes, including gelsolin, IDI1 and VDUP1. This, together with the low toxicity in normal cells, suggests that SAHA might have therapeutic potential for the treatment of human breast cancers.
         datePublished:2000-10-01T00:00:00Z
         dateModified:2000-10-01T00:00:00Z
         pageStart:849
         pageEnd:866
         sameAs:https://doi.org/10.1007/BF03401823
         keywords:
            Suberoylanilide Hydroxamic Acid
            Apoptosis-regulating Proteins
            Gelsolin
            Hybrid Polar Compounds (HPCs)
            Hematopoietic Tumor Cells
            Molecular Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig1.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig2.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig3.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig4.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig5.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig6.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig7.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig8.jpg
         isPartOf:
            name:Molecular Medicine
            issn:
               1528-3658
               1076-1551
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lili Huang
               affiliation:
                     name:Dana-Farber Cancer Institute
                     address:
                        name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
                        type:PostalAddress
                     type:Organization
                     name:Harvard Medical School
                     address:
                        name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Arthur B. Pardee
               affiliation:
                     name:Dana-Farber Cancer Institute
                     address:
                        name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
                        type:PostalAddress
                     type:Organization
                     name:Harvard Medical School
                     address:
                        name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
      description:Suberoylanilide hydroxamic acid (SAHA) is a prototype of the newly developed, second-generation, hybrid polar compounds. It is a novel histone deacetylase inhibitor with high potency for inducing cell differentiation of cultured murine erythroleukemia cells. Studies with SAHA have primarily been performed with hematopoietic tumor cells. Here we extent these studies with SAHA to human breast cancer cell lines in an attempt to find better therapeutic agents for breast cancer treatment. Human breast cancer cell lines, MCF7, MDA-MB-231, and MDA-MB-435, as well as normal cells, including the normal breast epithelial cell line MCF-10A, and fibroblasts, were treated with SAHA. Cells assayed for cell survival by using trypan blue exclusion assay, colony formation assay, and cell cycle and apoptosis analysis. The effects of SAHA on cell cycle and apoptosis regulatory proteins were examined by Western blots analysis. The identification of additional target genes was carried out by differential display (DD) and reverse transcription-polymerase chain reaction (RT-PCR). SAHA inhibited clonogenic growth of MCF7, MDA-MB-231, and MDA-MB-435 breast cancer cells. These cells were more sensitive to SAHA-mediated cytotoxic effects than normal breast epithelial cells and fibroblasts. The cytotoxic effects of SAHA on breast cancer cells were manifested by G1 and G2/M cell cycle arrest and eventual apoptosis. The pan-caspase inhibitor, Z-VAD.fmk, blocked SAHA-induced cell death, DNA laddering, and cleavage of poly(ADP-ribose) polymerase, indicating the involvement of caspases in SAHA-mediated apoptosis. In addition, SAHA modulated cell cycle and apoptosis regulatory proteins. For example, cyclin-dependent kinase (CDK) inhibitors p21WAF1/Cip1 and p27Kip1 were induced, and retinoblastoma protein pRb was hypophosphorylated. Moreover, SAHA induced several genes associated with differentiation and/or growth inhibition. These genes encode gelsolin, isopentenyl-diphosphate delta isomerase (IDI1), and 1,25-dihydroxyvitamin D-3 up-regulated protein 1 (VDUP1), the last two of which were identified by DD. Induction of these genes may contribute to SAHA-mediated pro-differentiating and antiproliferative effects. SAHA induced growth inhibition, cell cycle arrest, and eventual apoptosis in human breast cancer cells, possibly by modulating cell cycle and apoptosis regulatory proteins, such as CDK inhibitors p21 and p27, pRb, and other differentiation and/or growth inhibition-associated genes, including gelsolin, IDI1 and VDUP1. This, together with the low toxicity in normal cells, suggests that SAHA might have therapeutic potential for the treatment of human breast cancers.
      datePublished:2000-10-01T00:00:00Z
      dateModified:2000-10-01T00:00:00Z
      pageStart:849
      pageEnd:866
      sameAs:https://doi.org/10.1007/BF03401823
      keywords:
         Suberoylanilide Hydroxamic Acid
         Apoptosis-regulating Proteins
         Gelsolin
         Hybrid Polar Compounds (HPCs)
         Hematopoietic Tumor Cells
         Molecular Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig1.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig2.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig3.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig4.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig5.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig6.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig7.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2FBF03401823/MediaObjects/10020_2018_BF03401823_Fig8.jpg
      isPartOf:
         name:Molecular Medicine
         issn:
            1528-3658
            1076-1551
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lili Huang
            affiliation:
                  name:Dana-Farber Cancer Institute
                  address:
                     name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
                     type:PostalAddress
                  type:Organization
                  name:Harvard Medical School
                  address:
                     name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Arthur B. Pardee
            affiliation:
                  name:Dana-Farber Cancer Institute
                  address:
                     name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
                     type:PostalAddress
                  type:Organization
                  name:Harvard Medical School
                  address:
                     name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Molecular Medicine
      issn:
         1528-3658
         1076-1551
      volumeNumber:6
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dana-Farber Cancer Institute
      address:
         name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute
      address:
         name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lili Huang
      affiliation:
            name:Dana-Farber Cancer Institute
            address:
               name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
               type:PostalAddress
            type:Organization
            name:Harvard Medical School
            address:
               name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Arthur B. Pardee
      affiliation:
            name:Dana-Farber Cancer Institute
            address:
               name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
               type:PostalAddress
            type:Organization
            name:Harvard Medical School
            address:
               name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
      name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
      name:Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
      name:Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(286)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.45s.

LINK . SPRINGER . COM {}